pdatanews

Will the FDA approve any psychedelic substance for medical use this year?

Yes 16% (-2pp in 24h) on Kalshi as of 15:31 UTC on 18 Nov 2026 for “Will the FDA approve any psychedelic substance for medical use this year?”. The market has $2.6k in Kalshi-reported 24-hour volume. pdata.world compares it with 24 related events on Kalshi, Polymarket and Manifold.

Kalshi·Science and Technology
United States
marketsingle market
16%
▼ 2.0pp
24h change
vol cum
$447.9k
vol 24h
$2.6k
spread
0.03
ends
Jan 8, 2027
Yes 16¢
No 84¢

If the FDA approves any psychedelic substance for medical use for marketing before Jan 1, 2027, then the market resolves to Yes.

Psychedelic drugs include: LSD, Psilocybin, DMT, Mescaline, MDMA, MDA, PCP, DXM, Ibogaine, Salvia divinorum, 2C family, and Ayahuasca. Important information: For purposes of this Contract: The listed substances are illustrative, not exhaustive. Approval of any other substance commonly recognized in scientific or FDA documentation as a psychedelic, hallucinogen, or entactogen (for example, psilocin, 5-MeO-DMT, methylone, or 2C-, DOx-, or NBOMe-family compounds) may also satisfy the Payout Criterion. "Approval for medical use" means an FDA approval letter for an NDA or BLA authorizing marketing of a drug or biologic for human medical use in the United States, where a listed (or otherwise qualifying) psychedelic substance is an active pharmaceutical ingredient of the approved product. Complete Response Letters, tentative approvals, Emergency Use Authorizations, expanded access or compassionate use authorizations, and approvals limited to export do not satisfy the Payout Criterion. Combination products. Approval of a combination drug product satisfies the Payout Criterion only if at least one active ingredient is a listed (or otherwise qualifying) psychedelic substance and that psychedelic active ingredient has not previously been approved by the FDA via NDA or BLA for any human medical indication. By way of example, an FDA approval of AXS-05 (a combination of dextromethorphan and bupropion) for a new indication does not satisfy the Payout Criterion, because both active ingredients were FDA-approved prior to Issuance. New indications for previously-approved substances. An FDA approval (including via supplemental NDA or supplemental BLA) of a new medical indication, dosage, or formulation for a substance whose active pharmaceutical ingredient was already approved by the FDA via NDA or BLA prior to Issuance does not satisfy the Payout Criterion.

timeline
opened · Jul 17, 2025opencloses · Jan 8, 2027
Any psychedelic substance for medical use · prices over time
−24h
now
volume · 24h windows
no volume history

similar markets

suggested by pdata